According to the vaccine's maker, Valneva, the FDA based its decision to suspend the shot on four new serious adverse events ...

FDA suspends Ixchiq license, raising regulatory risks for Valneva. Key vaccines anchor revenue, but valuation concerns emerge ...

The FDA suspended Valneva’s U.S. license for its chikungunya vaccine Ixchiq due to serious safety concerns, multiple ...

Worrisome new signals caused the U.S. FDA – which earlier this month OK’d revised labeling for Valneva SE’s chikungunya virus ...

Valneva must immediately cease U.S. shipments and sales of Ixchiq, a vaccine for chikungunya virus. The FDA recently lifted a ...

HealthDay News — The US Food and Drug Administration (FDA) is suspending the biologics license for the live-attenuated chikungunya vaccine, Ixchiq, in the United States. The move comes after reports ...

Center for Biologics Evaluation and Research (CBER) has suspended the biologics license for Valneva’s Ixchiq (Chikungunya ...

The U.S. Food and Drug Administration (USFDA) has suspended the biologics license of Ixchiq (Chikungunya Vaccine, Live), ...

The suspension of the license is effective immediately and requires Valneva to stop shipping and selling of Ixchiq in the United States. The suspension follows the US FDA’s decision on August 6, 20251 ...

The agency said it had become aware of more reports of serious adverse events, leading center director Vinay Prasad to ...

The US Food and Drug Administration (FDA) announced late last week that it has suspended the license for French drugmaker ...

Analysts on Monday expressed divergent opinions on vaccine company Valneva SE (VALN) after the firm said that the United ...